Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3839500 | 1.00 | SLC18A3 (0.44) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL6659482 | 1.00 | SLC18A3 (0.44) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL5422025 | 0.96 | ALDH1A1 (0.46) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL20703762 | 0.96 | ALDH1A1 (0.46) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL8829142 | 0.96 | ALDH1A1 (0.46) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL5422028 | 0.96 | ALDH1A1 (0.46) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL250436 | 0.89 | SLC18A3 (0.46) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL12446288 | 0.89 | SLC18A3 (0.46) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL17226159 | 0.89 | SLC18A3 (0.46) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 | |
| SCHEMBL10048505 | 0.89 | SLC18A3 (0.46) | SLC18A3ALDH1A1TSHRCYP1A2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065490-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| EP-1529038-B1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-10-07 | — | — | EP | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | SLC18A3 957/4885ALDH1A1 829/4885TSHR 360/4885 |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | SLC18A3 957/4885ALDH1A1 829/4885TSHR 360/4885 |
| US-20150065490-A1 | ORGANIC COMPOUNDS | ADRB2, ADRA2C, ADRB1 | SLC18A3 861/4885ALDH1A1 226/4885TSHR 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.